NEW ORLEANS, Oct. 17, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 24, 2017 to file lead plaintiff applications in a securities class action lawsuit against Dr. Reddy’s Laboratories Ltd. (NYSE:RDY), if they purchased the Company’s securities between June 17, 2015 and August 10, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Get Help
Dr. Reddy’s investors should visit us at https://www.claimsfiler.com/cases/view-dr-reddys-laboratories-ltd-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Dr. Reddy’s and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company had failed to implement an effective corporate quality control system including but not limited to its manufacturing plants and (ii) as a result of the foregoing, Dr. Reddy’s financial statements were materially false and misleading at all relevant times.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.


Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 



